Cargando…

A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia

BACKGROUND: Severe hypoglycemic episodes are life-threatening events demanding rapid administration of glucagon by a caregiver or bystander. The glucagon analog dasiglucagon is stable in aqueous formulation and therefore suitable for delivery in a ready-to-use autoinjector, potentially increasing sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bailey, Naila Celeste, Dimsits, Jeannett, Hammer, Mette, Kendall, David M., Bailey, Timothy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057872/ https://www.ncbi.nlm.nih.gov/pubmed/34809479 http://dx.doi.org/10.1089/dia.2021.0367

Ejemplares similares

Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
por: Schaumleffel, Carol
Publicado: (2023)

Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model
por: Hinahara, Jordan, et al.
Publicado: (2022)

Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation
por: Valentine, Virginia, et al.
Publicado: (2019)

Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
por: Battelino, Tadej, et al.
Publicado: (2021)

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies
por: Christiansen, Mark P, et al.
Publicado: (2021)

“It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes
por: Hughes, Allyson S., et al.
Publicado: (2022)

Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia
por: Bajpai, Sanjay K, et al.
Publicado: (2022)

Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis
por: Maji, Shampa, et al.
Publicado: (2023)

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study
por: Yale, Jean-François, et al.
Publicado: (2017)

Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
por: Pontiroli, Antonio E., et al.
Publicado: (2022)

Severe Hypoglycemia and the Use of Glucagon Rescue Agents: An Observational Survey in Adults With Type 1 Diabetes
por: Hughes, Allyson S., et al.
Publicado: (2023)

Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
por: Giménez, Marga, et al.
Publicado: (2023)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes
por: Aronson, Ronnie, et al.
Publicado: (2023)

Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia
por: Pontiroli, Antonio E., et al.
Publicado: (2019)

Who Needs Epinephrine? Anaphylaxis, Autoinjectors, and Parachutes
por: Dribin, Timothy E., et al.
Publicado: (2023)

The pharmacokinetics of epinephrine/adrenaline autoinjectors
por: Dreborg, Sten, et al.
Publicado: (2021)

Leveraging Dissolution by Autoinjector Designs
por: Spangardt, Christoph, et al.
Publicado: (2022)

Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
por: Siafarikas, Aris, et al.
Publicado: (2012)

Accidental Digital Ischemia by an Epinephrine Autoinjector
por: Nayaz, Mohamed, et al.
Publicado: (2023)

Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study
por: Tehranchi, Ramin, et al.
Publicado: (2022)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia, Nitil
Publicado: (2011)

Adherence with epinephrine autoinjector prescriptions in primary care
por: Abrams, Elissa M., et al.
Publicado: (2017)

Development of an advanced injection time model for an autoinjector
por: Thueer, Thomas, et al.
Publicado: (2018)

Adherence to adrenaline autoinjector prescriptions in patients with anaphylaxis
por: Parke, Louise, et al.
Publicado: (2019)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016)

Comparison of drug delivery with autoinjector versus manual prefilled syringe and between three different autoinjector devices administered in pig thigh
por: Hill, Robert L, et al.
Publicado: (2016)

Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors
por: Barone, Donald A., et al.
Publicado: (2016)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey
por: Ross, Amy Perrin, et al.
Publicado: (2023)

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus
por: Hövelmann, Ulrike, et al.
Publicado: (2018)

Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery
por: Sclar, David Alexander
Publicado: (2013)

Autoinjectors Preferred for Intramuscular Epinephrine in Anaphylaxis and Allergic Reactions
por: Campbell, Ronna L., et al.
Publicado: (2016)

Accidental self-administration of an epinephrine autoinjector by a toddler
por: Edgerley, Sarah, et al.
Publicado: (2021)

Are adrenaline autoinjectors fit for purpose? A pilot study of the mechanical and injection performance characteristics of a cartridge-versus a syringe-based autoinjector
por: Schwirtz, Andreas, et al.
Publicado: (2010)

A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia()
por: Chabenne, Joseph, et al.
Publicado: (2014)

Mitochondrial GTP Insensitivity Contributes to Hypoglycemia in Hyperinsulinemia Hyperammonemia by Inhibiting Glucagon Release
por: Kibbey, Richard G., et al.
Publicado: (2014)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
por: Osumili, Beatrice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q42d96ummiqtace6cdriajs64v